Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8938090 | 0.98 | ALDH1A1 (0.57) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL31167601 | 0.85 | ALDH1A1 (0.71) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL503007 | 0.84 | TDP1 (0.68) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL11045034 | 0.82 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL3187747 | 0.82 | ALDH1A1 (0.57) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL3671008 | 0.79 | ALDH1A1 (0.63) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL8217879 | 0.79 | HTT (0.58) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL30641501 | 0.79 | ALDH1A1 (0.68) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL2904745 | 0.79 | ALDH1A1 (0.54) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL29273761 | 0.79 | ALDH1A1 (0.68) | ALDH1A1GAAMAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014106763-A1 | PYRIDOPYRAZINES AS ANTICANCER AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-07-10 | — | — | WO | disclosed |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-2035573-A1 | METHODS FOR IDENTIFYING MODULATORS OF EOXIN FORMATION | Biolipox AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| EP-1917246-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008001079-A1 | METHODS FOR IDENTIFYING MODULATORS OF EOXIN FORMATION | BIOLIPOX AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| EP-0973720-A1 | 2-SUBSTITUTED BENZOYL-CYCLOALKYL-1-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998040344-A1 | 2-SUBSTITUTED BENZOYL-CYCLOALKYL-1-CARBOXYLIC ACID DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-09-17 | — | — | WO | disclosed |
| EP-0262785-B1 | N-[2-(4-carboxymethoxyphenyl)-1-methylethyl]-2-hydroxy-2-(3-chlorophenyl)ethane amine, the methyl ester, salt and stereoisomeric forms thereof | BEECHAM GROUP PLC (GB) | 1993-10-20 | — | — | EP | disclosed |
| US-4405619-A | ANALGESICS | DIAMOND SHAMROCK CORPORATION (US) | 1983-09-20 | — | — | US | disclosed |
| EP-0088109-A1 | ANTIINFLAMMATORY SUBSTITUTED-1,2,4-TRIAZOLO(4,3-b)-1,2,4-TRIAZINES | DIAMOND SHAMROCK CORPORATION (US) | 1983-09-14 | — | — | EP | disclosed |
| WO-1983000864-A1 | ANTIINFLAMMATORY SUBSTITUTED-1,2,4-TRIAZOLOAD4,3-bBD-1,2,4-TRIAZINES | DIAMOND SHAMROCK CORP (US) | 1983-03-17 | — | — | WO | disclosed |
| EP-0028105-B1 | SECONDARY AMINES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1983-01-19 | — | — | EP | disclosed |
| US-4329358-A | 3-Chlorophenyl anti-obesity agents | BEECHAM GROUP LIMITED (GB) | 1982-05-11 | — | — | US | disclosed |
| EP-0040000-A1 | Arylethanolamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-11-18 | — | — | EP | disclosed |
| EP-0028105-A1 | Secondary amines, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-05-06 | — | — | EP | disclosed |
| US-4251527-A | ANTIINFLAMMATORY AGENTS | DIAMOND SHAMROCK CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4157392-A | HYPOTENSIVE AGENTS, ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS AND NERVOUS SYSTEM EFFECTS | DIAMOND SHAMROCK CORPORATION (US) | 1979-06-05 | — | — | US | disclosed |
| US-4046763-A | INTERMEDIATE FOR ULTRAVIOLET LIGHT ABSORBERS | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | CACNA1A, BMP4, TPX2 | ALDH1A1 3966/4885GAA 1216/4885MAPT 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.